Greene, Sarah E; Huang, Yuefang; Kim, Wooseob; Liebeskind, Mariel J; Chandrasekaran, Vinay; Liu, Zhuoming; Deepak, Parakkal; Paley, Michael A; Lew, Daphne; Yang, Monica; Matloubian, Mehrdad; Gensler, Lianne S; Nakamura, Mary C; O'Hallaran, Jane A; Presti, Rachel M; Whelan, Sean PJ; Buchser, William J; Kim, Alfred HJ; Weil, Gary J

doi:10.1016/j.jcvp.2023.100135

Download PDF

A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination

Published Web Location

https://doi.org/10.1016/j.jcvp.2023.100135

Abstract

Objective

Lateral flow assays (LFA) are sensitive for detecting antibodies to SARS-CoV-2 proteins within weeks after infection. This study tested samples from immunocompetent adults, and those receiving treatments for chronic inflammatory diseases (CID), before and after mRNA SARS-CoV-2 vaccination.

Methods

We compared results obtained with the COVIBLOCK Covid-19 LFA to those obtained by anti-spike (S) ELISA.

Results

The LFA detected anti-S antibodies in 29 of 29 (100%) of the immunocompetent and 110 of 126 (87.3%) of the CID participants after vaccination. Semiquantitative LFA scores were statistically significantly lower in samples from immunosuppressed participants, and were significantly correlated with anti-S antibody levels measured by ELISA.

Conclusions

This simple LFA test is a practical alternative to laboratory-based assays for detecting anti-S antibodies after infection or vaccination. This type of test may be most useful for testing people in outpatient or resource-limited settings.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content

For improved accessibility of PDF content, download the file to your device.

UCSF